Lenvatinib

證據等級: L5 預測適應症: 10

目錄

  1. Lenvatinib
  2. Lenvatinib: From Thyroid Cancer to Liposarcoma
    1. One-Sentence Summary
    2. Quick Overview
    3. Why is This Prediction Reasonable?
    4. Clinical Trial Evidence
    5. Literature Evidence
    6. Australia Market Information
    7. Cytotoxicity
    8. Safety Considerations
    9. Conclusion and Next Steps
    10. Disclaimer

## 藥師評估報告

Lenvatinib: From Thyroid Cancer to Liposarcoma

One-Sentence Summary

Lenvatinib is a multi-target tyrosine kinase inhibitor internationally approved for angiogenesis-driven cancers such as differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma. The TxGNN model predicts it may also be effective for liposarcoma, supported by 1 completed clinical trial and 4 publications, though the evidence base remains early-stage and the drug is not currently registered in Australia.


Quick Overview

Item Content
Original Indication Not specified in this evidence pack (data gap); internationally, lenvatinib is approved for differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma
Predicted New Indication Liposarcoma
TxGNN Prediction Score 99.51%
Evidence Level L3 (completed non-randomised Phase Ib/II trial + supporting literature)
Australia Market Status Not marketed
Number of ARTG Entries 0
Recommended Decision Hold

Why is This Prediction Reasonable?

Detailed, evidence-pack-sourced mechanism of action data is not available (flagged as a High-severity data gap; source: DrugBank). Based on widely known pharmacology, lenvatinib is an oral multi-kinase inhibitor targeting VEGFR1‑3, FGFR1‑4, PDGFRα, KIT and RET, and its established anticancer effect works primarily through anti-angiogenesis and inhibition of tumour vasculature.

Lenvatinib’s proven indications (thyroid, hepatocellular, renal cell carcinomas) are all solid tumours with strong angiogenic dependence. Liposarcoma — particularly dedifferentiated and myxoid subtypes — also shows vascular-driven growth, which provides a mechanistic rationale for anti-angiogenic TKIs. This is reinforced clinically: the LEADER study (NCT03526679) combined lenvatinib with eribulin (a mitotic-inhibitor chemotherapy already used in liposarcoma) and reported activity in advanced adipocytic sarcoma and leiomyosarcoma, supporting the plausibility of the TxGNN prediction.


Clinical Trial Evidence

Trial Number Phase Status Enrolment Key Findings
NCT03526679 Phase 1/2 Completed 30 Single-arm LEADER study of lenvatinib (anti-angiogenic) plus eribulin (mitotic chemotherapy) in inoperable/metastatic adipocytic sarcoma and leiomyosarcoma

Literature Evidence

PMID Year Type Journal Key Findings
36129471 2022 Phase Ib/II single-arm trial report Clinical Cancer Research LEADER study (NCT03526679) results on safety and efficacy of lenvatinib plus eribulin in advanced liposarcoma and leiomyosarcoma
39103896 2024 Translational/biomarker study Experimental Hematology & Oncology CDK4 as a prognostic biomarker in soft tissue sarcoma, with synergistic effect of CDK4 inhibition in sequential treatment of dedifferentiated liposarcoma
29848686 2018 Preclinical study Anticancer Research Broad-spectrum preclinical antitumour activity of eribulin combined with mechanistically differing anticancer agents, including liposarcoma models
34326745 2021 Case report Case Reports in Oncology Marked tumour size reduction in a dedifferentiated liposarcoma patient with lung/abdominal metastasis using individualised targeted therapy, surgery and chemotherapy

Australia Market Information

Lenvatinib currently has no ARTG entries and is not marketed in Australia (0 licences recorded).


Cytotoxicity

Item Content
Cytotoxicity Classification Targeted therapy (multi-target tyrosine kinase inhibitor / anti-angiogenic agent)
Myelosuppression Risk Low to moderate — TKIs generally cause less myelosuppression than conventional cytotoxics; risk increases when combined with a cytotoxic partner such as eribulin
Emetogenicity Classification Low to moderate
Monitoring Items Blood pressure (hypertension is a known class effect), FBC, liver function, renal function/proteinuria, thyroid function, ECG/QT interval
Handling Protection Oral hazardous/targeted agent — standard oral oncology handling precautions apply (avoid crushing/splitting, use gloves when handling)

Note: this profile reflects internationally known TKI-class characteristics; formal DrugBank/TGA toxicity data was not retrieved for this evidence pack.


Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information — key warnings, contraindications and drug interaction data were not available in this evidence pack (a Blocking-severity data gap for TFDA warning/contraindication data was flagged, preventing initial safety screening).


Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic rationale is plausible and one completed small (N=30) single-arm Phase Ib/II trial plus supporting literature show early activity in liposarcoma, but the evidence is not yet controlled/randomised, lenvatinib has no current Australian market presence (0 ARTG entries), and a Blocking-severity safety data gap prevents an initial safety assessment.

To proceed, the following is needed:

  • TGA/PI-sourced warnings, contraindications and drug interaction data (currently blocking)
  • Confirmed mechanism of action documentation from DrugBank
  • Larger controlled trial data (current evidence is single-arm, N=30)
  • Clarification of Australian regulatory pathway, given the drug is not currently registered

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.



Copyright © 2026 藥提醒科技有限公司 (yao.care). This report is for research purposes only and does not constitute medical advice.

This site uses Just the Docs, a documentation theme for Jekyll.